We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYTH
301
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-66,200
Closed -$2.47M
ZGNX
302
DELISTED
Zogenix, Inc.
ZGNX
– –
-32,063
Closed -$882K
GEVA
303
CALL
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
– –
-285
Closed -$1.84M
PCYC
304
DELISTED
PHARMACYCLICS INC
PCYC
– –
-2,860
Closed -$372K
RNA
305
PUT
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
– –
-120
Closed -$56K
CBST
306
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-1,329
Closed -$2.59M
AVNR
307
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-113,308
Closed -$432K
DNDN
308
DELISTED
DENDREON CORPORATION
DNDN
– –
-131,500
Closed -$393K
DNDN
309
PUT
DELISTED
DENDREON CORPORATION
DNDN
– –
-1,436
Closed -$429K
AMBI
310
DELISTED
Ambit Biosciences Corp
AMBI
– –
-65,000
Closed -$627K
CHTP
311
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-83,200
Closed -$369K
CHTP
312
PUT
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
– –
-2,509
Closed -$1.11M
DCTH
313
DELISTED
Delcath Systems Inc
DCTH
– –
-24,401
Closed -$1.59M
PATH
314
DELISTED
NUPATHE INC COM STK
PATH
– –
-89,751
Closed -$293K
PATH
315
PUT
DELISTED
NUPATHE INC COM STK
PATH
– –
-7,014
Closed -$2.29M
CYTR
316
CALL
DELISTED
CytRx Corp
CYTR
– –
-21
Closed -$78K
VVUS
317
CALL
DELISTED
Vivus Inc
VVUS
– –
-38
Closed -$342K
CELG
318
CALL
DELISTED
Celgene Corp
CELG
– –
-420
Closed -$3.55M
IMUC
319
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
– –
-625
Closed -$30.6K
OREX
320
CALL
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-226
Closed -$1.27M
MDVN
321
DELISTED
MEDIVATION, INC.
MDVN
– –
-150,032
Closed -$5.53M
MDVN
322
PUT
DELISTED
MEDIVATION, INC.
MDVN
– –
-9,836
Closed -$31.4M
KBIO
323
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
– –
-10,081
Closed -$356K
RPRX
324
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
– –
-265
Closed -$485K
OXGN
325
DELISTED
OXIGENE INC COM
OXGN
– –
-345,658
Closed -$871K
9 10 11 12
13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.